

Subject:	Percutaneous and Endoscopic Spinal Surgery	Publish Date:	06/28/2024
Document #:	SURG.00071	Last Review Date:	05/09/2024
Status:	Reviewed		

Description/Scope

This document addresses percutaneous and endoscopic spinal discectomy and disc decompression, as well as image-guided minimally invasive spinal decompression procedures.

During a percutaneous, endoscopic, or image-guided spinal procedure, the surgeon does not have direct visualization of the anatomic site with the naked eye. Visual guidance is provided indirectly using fluoroscopy or, if an endoscope is used, a video monitor. During open and minimally invasive procedures, the surgeon is able to directly visualize the operative site. This document does not address discectomy and disc decompression procedures under direct visualization with the naked eye, microscope, or loupe.

Note: Please see the following related documents for additional information:

- SURG.00052 Percutaneous Vertebral Disc and Vertebral Endplate Procedures
- SURG.00073 Epiduroscopy
- SURG.00111 Axial Lumbar Interbody Fusion
- SURG.00134 Interspinous Process Fixation Devices

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- Include the CPT or HCPCS code(s)
- Include a list of other state Medicaid agencies and private insurers who cover the service
- Include information about the health service from the U.S. Food and Drug Administration
- Include known risks of the service and health outcomes of others who have received it
- Include a list of covered alternative services, if any, that could be used to treat the condition
- Identify a specific recipient needing the service
- Include the recipient's health history
- Include the disease information necessitating the requested service
- Include a rationale for the immediacy of the review

Additional required information

- Submit the rationale used to preliminarily indicate the service is experimental/investigational
 - Include peer-reviewed journal articles in PDF format with links to the online articles
 - Include evidence-based clinical guidelines reviewed by the plan
- Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery**Position Statement****Investigational and Not Medically Necessary:**

Percutaneous or endoscopic spinal surgical techniques are considered **investigational and not medically necessary**.

Rationale*Percutaneous Discectomy and Disc Decompression*

Automated percutaneous lumbar discectomy (APLD) was introduced in the 1980s using a suction curettage device for disc removal. Initial case series focusing on lumbar disc disease reported encouraging results and the technique was widely adopted. However, controlled trials reported less impressive results. For example, Revel and colleagues reported on a controlled randomized study comparing chemonucleolysis and APLD (Revel, 1993). A total of 61% of those treated with chemonucleolysis reported favorable results compared to 44% in those treated with APLD. Chatterjee reported on the results of a randomized study that compared APLD with open surgical microdiscectomy (Chatterjee, 1995). A total of 29% of individuals in the APLD group reported satisfactory results compared to 80% in the microdiscectomy group.

The LAPDOG study was a randomized trial to compare APLD and open discectomy in individuals with lumbar disc herniation (Haines, 2002). This trial was designed to recruit 330 participants, but was only able to enroll 36. Of 27 evaluable participants, 41% of the percutaneous discectomy group and 40% of the conventional discectomy group were judged to have a successful outcome at 6 months. However, the authors concluded the trial was unable to enroll sufficient numbers to reach a definitive conclusion.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 - 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 - 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Amoretti and colleagues (2006) reported an uncontrolled case series of 50 individuals presenting with lumbar disc disease that were treated with a percutaneous discectomy probe, the DeKompressor® (Stryker, Inc., Kalamazoo, Michigan). This device, which received clearance from the U.S. Food and Drug Administration (FDA) through the 510(k) process in 2003, is used to aspirate disc material during percutaneous discectomies in the lumbar, thoracic, and cervical regions of the spine. When activated, the probe rotates to create suction and removes the nucleus pulposus. The clinical outcome measured in the Amoretti study was a visual analog scale (VAS) assessment of pain at 2, 7, 30, and 180 days following treatment. A decrease of baseline pain of more than 70% was observed in 39 of 50 individuals treated. Of the 39 individuals with a successful pain reduction outcome, 31 required no further medication therapies and the remaining 8 individuals were able to reduce medication therapies. A limitation of this study includes a lack of randomization for comparison of surgical versus non-surgical therapies.

In a 2007 Cochrane review of 40 randomized controlled trials of surgical interventions treating spinal disc disease, Gibson and Waddell found that microdiscectomy gives broadly comparable results to standard open discectomy. This review also concluded that considerable evidence exists that surgical discectomy provides effective clinical relief for select individuals with sciatica due to lumbar disc prolapse that fails to resolve with conservative management. Evidence suggested that surgical discectomy provides faster relief from an acute attack of sciatica, but its impact on the long-term natural history of underlying disc disease was unclear. There was a lack of evidence to establish the efficacy and safety of automated percutaneous discectomy, coblation therapy, and laser discectomy.

In a 2014 Cochrane review, Rasouli and colleagues compared the benefits and harms of minimally invasive discectomy (MID) procedures to microdiscectomy or open discectomy. They included 11 randomized controlled trials or quasi-controlled trials (n=1172) that compared conventional surgery to percutaneous endoscopic lumbar discectomy (PELD), transmuscular tubular microdiscectomy, or APLD. Primary outcomes included pain related to sciatica or low back pain (as measured by a VAS) and sciatic specific outcomes. They found that 7 out of 11 studies had a high overall risk of bias. MID procedures were found to be potentially inferior for relief of leg pain, lower

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

back pain and rehospitalization. Differences in pain relief were small and may not have been clinically significant. MID had the advantage of lower risk of infection. They recommended more research to define appropriate indications for MID as an alternative to conventional surgery.

Percutaneous Laser Discectomy and Disc Decompression

Ahn and colleagues (2004) reported on a case series of 111 consecutive individuals undergoing cervical laser discectomy. With a mean follow-up of 49.4 months, the outcomes were considered either excellent or fair in 80% of individuals. Hellinger and colleagues reported on a case series of 42 individuals with thoracic discogenic pain who were treated with laser discectomy (Hellinger, 2003). At 6 weeks, 41 of the 42 individuals were considered to have a successful outcome. However, the lack of a control group and randomization limits scientific interpretation of either of these studies.

In a multicenter, randomized controlled trial, Brouwer and colleagues (2015) compared the effectiveness of percutaneous laser disc decompression to traditional surgical microdiscectomy for individuals with sciatica from lumbosacral disc herniation. The researchers included 115 participants who were randomized 1:1. Inclusion criteria included sciatica refractory to 6-8 weeks of conservative management, ages 18-70, disc herniation verified by magnetic resonance imaging (MRI), and herniated fragment size smaller than one-third of the spinal canal. The primary outcome was self-reported functional disability on the Roland Morris Disability Questionnaire (RDQ) for sciatica. At a 1-year follow-up, the primary outcome was analyzed for the laser group (n=53) and the surgery group (n=54). The RDQ showed non-inferiority of the laser group at 8 weeks (-0.1; 95% confidence interval [CI], -2.3 to 2.1) and at 52 weeks (-1.1; 95% CI, -3.4 to 1.1) compared to the surgery group. The surgery group had a higher speed of recovery (hazard ratio [HR] 0.64; 95% CI, 0.42 to 0.97) and less re-operations; a total of 24 participants (44%) in the laser group underwent additional surgery during the first year compared to 9 participants (16%) in the surgery group. For 5 participants (9%), the laser treatment could not be performed due to laser malfunction or

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

inability to reach the disc space. At a 2-year follow-up (laser group n=48, surgery group n=51), the researchers did not find a significant difference between the two groups (Brouwer, 2017). However, the re-operation rate for the laser group was 52% compared to 21% in the surgery group. The researchers concluded that percutaneous laser disc decompression, followed with surgery when symptoms were not relieved, had comparable outcomes to traditional microdiscectomy surgery alone. They stated that further comparative studies are needed.

Percutaneous Nucleoplasty Discectomy and Disc Decompression

Nardi and colleagues (2005) studied 50 consecutive individuals who underwent a cervical disc nucleoplasty and reported that 80% had pain resolution. Although the results were encouraging, the study authors acknowledged the limited participant numbers and need for longer follow-up.

Gerszten and colleagues (2006) reported a prospective nonrandomized longitudinal cohort study of 67 participants with a contained lumbar disc herniation who underwent nucleoplasty in an outpatient setting. In this study, the authors evaluated pain, functioning, and quality of life (QOL) pre and postoperatively. The authors found that compared with preoperative QOL, there was a statistically significant improvement in QOL at 3 and 6 months. In another prospective study (n=69), Al-Zain and colleagues (2008) reported 1-year outcomes for lumbar nucleoplasty, which showed a statistically significant reduction in analgesic consumption, disability, and occupational incapacitation. However, both of these studies had limited follow-up and were not randomized or controlled.

Calisaneller and colleagues (2007) studied 29 individuals who underwent lumbar nucleoplasty and found that there were statistically significant reductions ($p < 0.001$) in VAS scores post-operatively as compared to preoperative values. The authors concluded that although nucleoplasty appeared to be a safe minimally invasive procedure, the

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

value of this new technique for the treatment of discogenic low back pain remains unproven. Further randomized placebo-controlled studies with longer follow-up are needed.

Abrishamkar and colleagues (2018) reported on a randomized clinical trial that compared open cervical discectomy to nucleoplasty. A total of 70 participants were enrolled; however, 13 participants discontinued the study leaving 28 in the nucleoplasty group and 29 in the cervical discectomy group. The participants were followed for 6 months and evaluated using the VAS for pain. The researchers did not find a significant pain difference between the two groups and did not observe any discitis, infection, or hematomas. In the nucleoplasty group, 1 subject had a repeat procedure, and 1 subject continued to have pain after 6 months. In the cervical discectomy group, 1 subject continued to have radicular pain 6 months post-surgery. Overall satisfaction was not significantly different between the two groups. The authors concluded that nucleoplasty was as effective as traditional cervical discectomy. The study had limited follow-up duration.

Percutaneous Endoscopic Discectomy and Disc Decompression

Lee and colleagues (2009) compared percutaneous endoscopic lumbar discectomy (PELD) with open lumbar microdiscectomy (OLM) in a retrospective study. Between December 2004 and May 2006, 54 individuals who underwent surgery, either PELD (25 participants) or repeated OLM (29 participants), due to recurrent disc herniation at L4-5 level, were selected and divided into two groups according to the surgical methods with sequestered disc, calcified disc, severe neurological deficit, or instability. Pain analysis before and after surgery was assessed using the VAS scoring (0-10) and function was assessed by the Oswestry Disability Index (ODI) in percent (0-100%). Radiographs and MRI imaging were also reviewed pre- and post-operatively. The PELD procedure used local anesthesia and fluoroscopic guidance to reach the treatment site. An obturator was inserted along the guide wire and hammered into place when reaching the annulus allowing a working cannula to the disc. An endoscope was inserted and the blue-stained disc material was removed. The OLM procedure was performed

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

under general anesthesia. A 2-3 cm incision was made and paravertebral muscles were dissected. The operating field was exposed and viewed via surgical microscope for discectomy and decompression. The authors found that the outcomes were favorable in both groups; PELD having the advantage with anesthesia, operative time and hospital stay. However, due to the size and design of the study, no firm clinical conclusions could be drawn regarding efficacy.

Peng and colleagues (2009) indicated that while PELD is a relatively new technique, few studies have reported the clinical outcome of PELD regarding QOL and return to work. In a retrospective study of 55 participants, clinical outcomes were reviewed using the North American Spine Score (NASS), Medical Outcomes Study Short Form-36 scores (SF-36), the VAS, and return to work. The treatment sites varied as well as the disc status. A total of 39 participants (70.9%) had L4-L5 discectomy, 12 (21.8%) had L5-S1 discectomy, 2 (3.6%) had L3-L4 and 2 (3.6%) had two levels L4-L5 and L5-S1 performed. There were 44 (80%) disc protrusions, 10 (18.2%) extrusions and 1 (1.8%) sequestered disc. The mean follow-up period was 3.4 years (range 2.0-6.5 years). All who were working preoperatively returned to work. The mean time to return to work was 24.3 days (range 10-60 days). Back pain and lower limb symptoms were confirmed by reduced NASS and VAS scores ($p < 0.05$) at 6 months and 2 years. There were improvements in QOL (SF-36, $p < 0.05$) scores except for general health at 6 months and 2 years post-surgery. The recurrence rate was 5% or 3 participants who subsequently underwent lumbar fusion for persistent back pain. The limitations of the study were that it was retrospective, uncontrolled, and limited in size.

Coverage Policy Recommendations from the North American Spine Society (NASS) state that endoscopic discectomy should “be covered treatment of lumbar disc herniation with radiculopathy.” According to information on the NASS website, the Coverage Policy Recommendations were created using “an evidence-based approach to spinal care when possible. In the absence of strict evidence-based criteria, policies reflect the multidisciplinary and non-conflicted experience and expertise of the authors in order to reflect reasonable standard practice indications in

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health’s Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient’s health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

the United States.” The authors also state that the coverage recommendations are not representative of a “standard of care” and should not be viewed as “fixed treatment protocols” (NASS, 2014).

Zhou and colleagues (2018) performed a retrospective study to assess the complications of percutaneous endoscopic lumbar discectomy (n=320) and percutaneous endoscopic interlaminar discectomy (n=106). The researchers evaluated participants at least 1 year post-procedure and based their assessment on the VAS and ODI. Common complications included: incomplete removal of herniated discs (1.4%; 6/426), recurrence (2.8%; 12/426), nerve root injury (1.2%; 5/426), dural tear (0.9%; 4/426), and nerve root induced hyperalgesia or burning-like nerve root pain (2.3%; 10/426). Less common complications included: the working channel passing through the canal into the disc space (1 case), super-elastic nerve hook trapped by exiting nerve root (1 case), epidural hematoma (1 case), radicular artery injury and massive bleeding (1 case), and intraoperative seizure (1 case). The authors concluded:

Because of the difficult learning curve and the lack of skill with requisite surgical techniques and clinical care of postoperative patients, different kinds of problems can arise with some frequency, especially when unique complications cause severe injury for the patient. Surgeons should vigilantly make adequate technical considerations and thoroughly understand patient anatomy to avoid unusual complications. Also, a high index of suspicion and early detection are important to prevent progressive neurological deficits or other adverse events.

Microendoscopic discectomy (MED)

Microendoscopic discectomy has been proposed as treatment of symptomatic lumbar herniated disc. Schizas and colleagues (2005) reported the results of a study of 28 individuals, 14 having MED and 14 having microdiscectomy. They found no difference of clinical significance between the outcomes of the two groups. The

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health’s Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient’s health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

authors concluded that MED was as least as effective as microdiscectomy for the treatment of uncontained or large contained disc herniations.

Righesso and colleagues (2007) reported a randomized study comparing MED with open discectomy (OD). A total of 19 participants were in the OD group and 21 were assigned to the MED group. The only statistically significant differences found were for size of the incision, length of hospital stay, and operative time. The former were greater in the OD group while operative time was greater in the MED group. Those differences did not affect the overall clinical and neurological outcomes which were comparable between the two groups.

Liu and colleagues (2010) conducted a retrospective study in consecutive participants with lumbar disc herniation treated with percutaneous lumbar discectomy (PLD) or MED in a single hospital from January 2000 to March 2002. A total of 104 PLD participants and 82 MED participants were included in the study with a mean follow-up period of 6.64 ± 0.67 years and 6.42 ± 0.51 years, respectively. There were no significant differences between the two groups in age, number of lesions, major symptoms and physical signs, and radiological findings. All participants were followed up with MacNab criteria and self-evaluation questionnaires comprising the ODI and Medical Outcomes Study 36-Item Short-Form Health Survey. The PLD procedure was performed by interventional radiologists utilizing automated percutaneous discectomy instrumentation under fluoroscopic guidance. The MED procedure was performed by orthopedists using a guide wire and serial dilators to access the operative site followed by an endoscope used as an operative channel. A total of 10 participants underwent subsequent open surgery in different durations, after PLD (8 participants) and 2 participants after MED. According to the MacNab criteria, 75.96% in the PLD group and 84.15% in the MED group achieved excellent or good results, respectively; this was statistically significant ($p=0.0402$). Findings of the Medical Outcomes Study 36-Item Short-Form Health Survey were 75.88 (PLD) vs. 81.86 (MED) group ($p=0.0582$). Two participants (2.44%) in the MED group had complications while there were no complications in the PLD group. Although both PLD and MED showed an acceptable long-term efficacy for treatment of lumbar disc herniation, the long-term satisfaction was lower in the

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

PLD groups. The authors acknowledged limitations of the study in the areas of follow-up, lack of long-term radiological examinations, and the low number of participants given the incidence of discogenic pathology. Other limitations included the retrospective, non-randomized study design.

Casal-Moro and colleagues (2011) reported a case series of 120 individuals who underwent MED for lumbar disk herniation in a prospective study with a 5-year follow up. The participants had symptomatic disk herniation with contained, non-contained, migrated or foraminal herniation. The most commonly affected level was L5-S1. Post operatively, statistically significant reductions in the VAS pain score (to evaluate preoperative and postoperative back and leg pain) and ODI scores (to evaluate functional state) were reported. The modified MacNab classification (see definitions) was also used as an outcome measure. Using the MacNab criteria, the authors reported good results in 89 individuals, fair results in 22 individuals, and poor results in 9 individuals. No excellent results were reported. Seven participants experienced intraoperative complications. Incidental durotomy occurred in 5 individuals; of this group, 3 required open surgery for repair. Other complications included a bayoneted rongeurs rupture requiring open surgery and a nerve root puncture. The study was limited by the lack of a control group comparison.

Garg and colleagues (2011) conducted a randomized controlled study to compare the outcomes of MED versus open discectomy for lumbar disc herniation. A total of 80 men and 32 women between the ages of 26-57 with a single-level disc herniation were randomized to undergo MED (n=55) or open (fenestration/laminotomy) discectomy (n=57). The participants were assessed pre- and post-operatively (at week 6, month 6, and year 1). Assessments included a clinical examination, radiological examination including MRI, and an electrophysiological study. Functional outcomes and low back pain were self-evaluated using the Oswestry low back pain disability questionnaire¹³ and were assessed by an independent observer. The outcome was considered satisfactory if radicular symptoms ceased, tension signs became negative, and the individual returned to his/her previous occupation or normal activities. In the MED group, surgical and anesthesia times were significantly longer, but

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

blood loss and hospital stay were significantly reduced. Improvement in the Oswestry score in both groups was significant at week 1 but not at other follow-ups. The rate of complication was similar in both groups. One participant in the MED group experienced a recurrence of disc herniation after 7 months and was treated with open discectomy. The authors concluded that both methods are equally effective in relieving radicular pain. MED resulted in a shorter hospital stay, less morbidity, and earlier return to work. The authors cautioned that with the MED, the surgical technique is demanding and should not be attempted without specific instruction and training. Limitations of this study included the short follow-up period (12-18 months) and the lack of quantitative outcome assessment. The authors also did not describe the method of randomization. Larger groups of participants with longer follow-up are needed to confirm these results.

Hussein and colleagues (2014) reported the outcomes of 200 individuals randomized to receive either microendoscopic lumbar discectomy (n=95) or open lumbar discectomy (n=90). Study participants and investigators were not blinded to the treatment assignments. At 8 years follow-up, data was available for 185 participants. A total of 15 participants were lost to follow-up, 10 due to subsequent same-level fusion, 3 due to death which was unrelated to the surgical procedure, and 2 who did not respond to follow-up telephone calls. Primary outcomes data included the Numerical Rating Scale (NRS) for back and leg symptoms and the ODI to quantify pain and disability. Objective outcomes data included blood loss, operative time, postoperative analgesics, length of hospital stay, time to return to work, reoperation and complication rate, participant satisfaction index (PSI), and modified (MacNab) criteria. Relief of leg pain was statistically significant for both groups, with no significant difference between the groups. Amongst participants in the endoscopic group, back pain was significantly improved throughout the entire follow-up period. However, in the open lumbar discectomy group, the significant improvement in back pain after surgery deteriorated over time; at the 8 years follow-up, back pain scores in this group had worsened significantly from preoperative scores. No serious complications were reported in either group. Additional well-designed RCTs with long-term follow-up are needed to confirm these results.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Image-guided minimally invasive lumbar decompression (MILD®) for Spinal Stenosis

Image-guided minimally invasive lumbar decompression (MILD) is being investigated as a treatment for lumbar spinal stenosis. Linggreen and colleagues (2010) conducted a retrospective review of self-reported improvement and post-procedure findings after MILD. A total of 42 consecutive participants between the ages of 52-86, with spinal stenosis and ligamentum flavum hypertrophy as the primary feature on MRI, were included in the study. All of the surgical procedures were performed by two interventional pain management physicians working at the same center. The results of self-reported pre- and post-procedure VAS, markers of global function, major and minor adverse events, self-reported outcomes, and need for follow-up procedures were evaluated. Measurements of functional improvement were assessed by ability to stand and ambulate for greater than 15 minutes, whereas prior to the procedure 98% reported significant functional limitations. VAS decreased by 40% from baseline and no major adverse events were reported. The most frequently reported minor adverse event was soreness lasting 3.8 days. Five of the study participants requested post-procedure opioid analgesia. Thirty-six participants indicated they would recommend this procedure, 1 was unsure, and 5 indicated they would not recommend the procedure. A total of 8 participants reported marginal improvement (change < 3 on VAS) yet 4/8 participants in this category still stated they would recommend MILD to others. The authors concluded that the MILD procedure appears to be a safe and likely effective option. Limitations of this study include its uncontrolled design.

Chopko and colleagues (2010) assessed the safety and functional outcomes of the MILD procedure as a treatment of symptomatic central canal spinal stenosis. This multicenter, non-blinded prospective study consisted of 78 participants who underwent the MILD procedure. Measures of outcomes included the VAS, ODI, Zurich Claudication Questionnaire (ZCQ), and SF-12v2 Health Survey at baseline and at 6 weeks post-treatment. The authors reported that at 6 weeks post-treatment the VAS, ZCQ, and SF-12v2 all reflected a reduction in pain. The ODI, ZCQ, and SF-12v2 reflected an improvement in physical function and mobility. The authors concluded that

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

the MILD procedure was safe, improved mobility, and reduced the pain associated with lumbar spinal canal stenosis. Limitations of the study included the lack of a control group and short follow-up.

Brown and colleagues (2012) reported the results of a double-blind, randomized, prospective study of epidural steroid injections (ESI) and the MILD procedure at a single pain management center. A total of 38 individuals with symptomatic lumbar spinal stenosis (LSS) participated in the study and were randomized into two treatment groups: 21 participants in the MILD arm and 17 individuals in the ESI arm. Outcome measures were reported using the VAS, the ODI, and ZCQ patient satisfaction score. The authors reported that at 6 weeks, the MILD participants improved from an average VAS baseline of 6.3 (95% CI $\pm$ 0.7) to a mean of 3.8 (95% CI $\pm$ 1.3). The ESI group had a mean VAS score of 6.4 (95% CI $\pm$ 1.0) at baseline compared with 6.3 (95% CI $\pm$ 1.4) at 6 weeks follow-up. Using the ODI, at 6 weeks follow-up, participants in the MILD group demonstrated a decrease from a baseline mean ODI from 38.8 (95% CI $\pm$ 4.2) to 27.4 (95% CI $\pm$ 7.0). In the ESI group, the initial ODI was 40.5 (95% CI $\pm$ 5.9) and at 6 weeks follow-up, the ODI was 34.8 (95% CI $\pm$ 8.2). In the MILD group, there was no significant change in the VAS and ODI scores from weeks 6 to 12. Participants in the ESI group were not measured at week 12. The ZCQ difference between the MILD group and the ESI group was not significant at week 6. Participants were allowed to cross over from the ESI group to the MILD group before 12 weeks, and eventually all of the participants in the ESI group had the MILD procedure. A total of 14 of the 17 participants in the cross-over ESI group experienced an improvement in their VAS scores after the MILD procedure. A limitation of the study included its short follow-up.

In another study, Chopko (2013) evaluated the long-term effectiveness and safety of MILD as a treatment of neurogenic claudication associated with lumbar spinal stenosis. The 2-year data are reported for 45 participants that were treated with MILD at 11 U.S. facilities. Outcome measurements included the VAS, ODI, and ZCQ. Interim data on the participants are included for 1 week, 6 months, and 1 year follow-up. The authors reported that at 2 years, the participants demonstrated a statistically significant reduction of pain as measured by VAS and significant improvement in physical function and mobility as measured by ZQC and ODI. The authors also reported major

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

improvement occurred by 1 week follow-up and showed no difference between each subsequent follow-up, suggesting considerable stability and durability of the initial result over time. There were no major adverse events or complications related to the procedure. Limitations of this study include its uncontrolled design.

In 2014, the Centers for Medicare & Medicaid Services (CMS) determined that percutaneous image guided lumbar decompression (PILD) for lumbar spinal stenosis (LSS) is not reasonable and necessary under section 1862(a)(1)(A) of the Social Security Act. The decision memo also states the following regarding the PILD procedure for LSS:

In reviewing the evidence on PILD we are confronted with weak studies, questions about missing information, questions about adverse events and conflicts of interest. After thoroughly reviewing the evidence for PILD for LSS, we have determined the evidence does not support a conclusion of improved health outcomes for our Medicare beneficiaries. However, we recognize that LSS is a real and important source of pain and functional limitation for patients, and that the development of effective minimally invasive procedures could have a potential place in the treatment armamentarium, but that more evidence is clearly needed. In order to support additional research on the development of effective minimally invasive procedures for the treatment of LSS, we will cover this procedure under section 1862(a)(1)(E) of the Social Security Act (CMS, 2014).

Benyamin and colleagues (2016) performed the industry-supported, multicenter, MiDAS ENCORE randomized controlled trial to assess outcomes of MILD compared to ESI in individuals with lumbar spinal stenosis and neurogenic claudication symptoms. A total of 302 participants were enrolled who were 65 years old or older, had refractory neurogenic claudication for at least 3 months, and had ligamentum flavum greater than 2.5 mm. After 28 participants withdrew before the study started, the remaining participants received the MILD procedure (n=143) or

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 - 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 - 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

up to four epidural steroid injections (n=131). At a 1-year follow-up, there were no significant differences between the groups for medication usage. However, for the MILD group, the ODI was significantly higher (58.0% versus 27.1%; $p<0.001$), as were the numeric pain rating scale (NPRS) scores (difference of 30.2%; $p<0.001$), ZCQ scores (difference of 20.0%; $p=0.001$), and the satisfaction score (2.4 ± 0.1 versus 3.1 ± 0.1 ; $p<0.001$). A total of 2 participants in each group had adverse events, the worst being 1 MILD subject having a non-serious procedural hemorrhage and 1 ESI subject having sinus bradycardia after treatment that was resolved with no complications. The authors concluded that MILD is statistically superior to epidural injections for lumbar spinal stenosis with neurogenic claudication. Limitations of the study included lack of blinding in the participants, potential high non-responder rates, enrollment not limited to participants that had never received epidural steroid injections, and loss to follow-up (22 participants in the MILD group and 32 in the ESI group withdrew before the 1-year follow-up).

Staats and colleagues (2018) published 2-year results of the MiDAS ENCORE study (Benyamin, 2016) to establish long-term safety and efficacy of MILD for the treatment of lumbar spinal stenosis with neurogenic claudication. At 2 years, 99 out of the original 143 participants were available for follow-up. At 2 years, ODI improved by 22.7 points (95% CI, 18.5 to 26.9), NPRS improved by 3.6 points (95% CI, 3.1 to 4.2), and ZCQ symptom severity improved by 1.0 point (95% CI, 0.8 to 1.2) and physical function domains improved by 0.8 point (95% CI, 0.6 to 0.9). The mean change from baseline exceeded the clinically meaningful threshold and achieved statistical significance for all efficacy end points and follow-up times ($p<0.001$). Responder rates for ODI, NPRS, and ZCQ symptom severity, physical function and patient satisfaction were 72.4%, 71.7%, 73.5%, 59.6% and 76.8%, respectively. None of the participants underwent a subsequent MILD procedure; however, out of the original 143 participants, 8 underwent a subsequent surgical procedure at the index level, 22 had an ESI or nerve block at the level of surgery (1 of which also received a spinal cord stimulator), 1 received a rhizotomy at the index level, and 1 received an intrathecal infusion pump. There were no serious adverse events reported. Limitations of the study included lack of a control group at 2 years and loss to follow-up.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Other Percutaneous and/or Endoscopic Spine Surgery Procedures

Chen and colleagues (2015) reported the results of an 8 year study highlighting the effectiveness of a computed tomography (CT)-assisted endoscopic procedure in the treatment of infectious spondylodiscitis in the thoracic and lumbar spine of immunocompromised individuals. A total of 41 participants with infectious spondylodiscitis underwent percutaneous endoscopic surgery with local anesthesia, and 13 participants (5 males and 8 females) with lesions on the thoracic or upper lumbar spine were selected for evaluation. The participants were between the ages of 49-84 years (median age of 65.6 years) and had a variety of comorbidities including but not limited to congestive heart failure, diabetes mellitus, coronary heart disease and hypertension. In the study, there was no mention of what happened to the other 28 participants or how participants were selected to have their lesions evaluated. Additionally, the authors lacked a comparison to the gold standard of CT-guided incision and drainage.

Researchers are exploring the use of percutaneous posterior cervical nerve root decompression using an expandable intervertebral cervical cage and concomitant posterior arthrodesis as a treatment for single-level cervical radiculopathy due to spondylosis. McCormack and colleagues (2013) reported the 1-year results of a prospective multicenter single-arm study that assessed clinical and radiographic outcomes of individuals with cervical radiculopathy due to spondylosis and stenosis who were treated at a single level with the DTRAX[®] Facet System (Providence Medical Technology, Walnut Creek, California, United States). A total of 60 individuals with symptomatic clinical radiculopathy and who had failed conservative treatment were included in the study. Preoperative assessments were conducted using the Neck Disability Index, VAS, QOL questionnaire (Short Form-12 version 2), CT scans, MRI, and dynamic radiographs. All participants underwent percutaneous posterior bilateral facet implantation consisting of a screw and expandable washer and iliac crest bone aspirate. Study participants were assessed postoperative at 2 weeks, 6 weeks, 3 months, 6 months, and 1 year with validated outcome questionnaires. Changes in segmental and overall cervical lordosis, foraminal dimensions, device retention and fusion criteria were evaluated for up to 1 year with CT reconstructions and radiographs. Fusion criteria were

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

defined as bridging trabecular bone between the facets, translational motion less than 2 mm, and angular motion less than 5°. All participants were postoperatively followed for 1 year. Participants in the study ranged from 40 to 75 years, with a mean of 53 years. A total of 42 individuals were treated at C5-6, 8 at C6-7, 7 at C4-5, and 3 at C3-4. Of the 60 participants, 56 had bilateral implants; 4 had unilateral implants due to intraoperative facet fracture (n=2) and inability to access the facet (n=2). The Neck Disability Index, VAS, and QOL questionnaire were significantly improved at 2 weeks and continued to be significantly improved up to 1 year. At the treated level, 93% of participants demonstrated intrafacet bridging trabecular bone on CT scans, translational motion was less than 2 mm in 100% and angular movement was less than 5° in 83% at the 1-year follow-up. There was no significant alteration in overall cervical lordosis. There was a 1.6° decrease in segmental lordosis at the treated level at 1 year that was significant. Foraminal width, volume, and posterior disc height had significantly increased at the 6 month follow-up but returned to baseline levels by 1 year. No significant decline in foraminal width and height at adjacent levels was reported. No reoperations or surgery- or device-related complications, including implant failure or retained hardware, were reported. Based on the results of this study, the authors concluded that the DTRAX Facet System is a safe and effective treatment for cervical radiculopathy. Limitations of this study include the lack of a control group and the limited follow-up duration (1 year).

Sieminonow and colleagues (2016) reported the 2-year clinical and radiographic results of treatment for single-level cervical radiculopathy using the DTRAX cage. A total of 53 of the original 60 participants reported on in the study reported by McCormack and colleagues in 2013 (88%) were available at the 2-year follow-up. The 2-year clinical and radiologic outcomes were similar to those reported at 1 year. The mean preoperative and 2-year scores were VAS Neck Pain: 7.4 versus 2.6 (p<0.0001); VAS Arm Pain: 7.4 versus 2.6 (p<0.0001); SF-12 Physical Component Summary: 34.6 versus 43.6 (p<0.0001), NDI: 32.3 versus 9.1 (p<0.0001); and SF-12 Mental Component Summary: 40.8 versus 51.4 (p<0.0001). Participants experienced a slight but statistically significant decrease in the posterior disk height at the treated level at 2-year follow-up. Radiographic fusion rate was 98.1%. No device failure, implant lucency or surgical reinterventions were reported. The authors concluded that indirect

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

decompression and posterior cervical fusion using the expandable intervertebral cage may be an effective tissue-sparing option in select individuals with single-level cervical radiculopathy. As with the initial report by McCormack, this study is limited by the lack of a control group and relatively short follow-up duration (now 2 years). Several authors in both studies had consulting relationships with the study sponsors. Sieminonow noted that a randomized controlled study would be needed to show the comparative effectiveness of the DTRAX technique.

Gibson and colleagues (2017) conducted a randomized controlled trial to compare transforaminal endoscopic discectomy (TED) (n=70) to traditional surgical microdiscectomy (n=70). Outcome measures were assessed preoperatively and at 3, 12, and 24 months. Inclusion criteria included ages 25-70, single-level prolapse with exiting and/or traversing nerve root compression, failure of conservative management > 6 weeks. Exclusion criteria included upper lumbar disc disease (L2/3 or above), previous disc prolapse, massive sequestered disc prolapse, weight > 115 kg, and malignancy. After 2 years post-procedure, there was not a significant difference in the QOL measurement on the short-form 6D survey nor postoperative work status. The TED group had a shorter length of hospital stay ($0.7 \text{ days} \pm 0.7$, range 0-2 versus $1.4 \text{ days} \pm 1.3$, range 0-9; $p < 0.001$). The VAS leg pain score was significantly less for the TED group (1.9 ± 2.6 versus 3.5 ± 3.1 ; $p = 0.002$). While there were no major complications for either group, 2 participants from the TED group had significant headaches post-procedure (resolved after bed rest) and 4 participants had dysaesthesia (resolved within 2-4 weeks); a subject in the microdiscectomy group had foot drop. The revision rate was higher in the TED group (5 participants versus 2; RR 2.62 [0.49 to 14.0]). The authors concluded that TED had comparable outcomes to microdiscectomy. Limitations of the study included lack of blinding, a difference in anesthesia techniques, and loss to follow-up (13 participants; 9.3%).

Summary

Additional well-designed studies comparing conventional (open approach) procedures to a percutaneous, endoscopic, or image-guided spinal decompression are needed. High quality randomized controlled trials with

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

sufficiently large sample sizes and longer follow-up periods are needed to determine if percutaneous and endoscopic spinal surgery procedures are more effective than conventional (open approach) procedures.

Background/Overview

Spinal surgery is generally performed in the cervical and lumbar regions of the spine because the degree of mobility in these areas is greater and can cause misalignment and instability of the vertebral structures. Disc disease is most common and usually due to a protrusion (herniation) of a vertebral disc. The disc may tear through surrounding tissue (annulus fibrosus), resulting in an extruded disc, or may remain intact but stretched resulting in a contained disc prolapse, compressing one or more nerve roots and resulting in pain, numbness, or weakness. Percutaneous discectomy and disc decompression have been investigated over the years as a treatment of back pain related to disc disease and bone structure.

Techniques using imaging for guidance include automated percutaneous lumbar discectomy (APLD), laser discectomy, and nucleoplasty. APLD involves the percutaneous insertion of a probe into the disc space with fluoroscopic guidance and then physical removal of the disc material using a suction curettage device. For laser discectomy, a variety of different lasers have been investigated, including the YAG, KTP, holmium, argon, and carbon dioxide lasers. Regardless of the type of laser, the procedure involves placement of the laser probe within the nucleus under fluoroscopic guidance. Due to differences in absorption, the energy requirements and the rate of application differ among the lasers. Additionally, it is unknown how much disc material must be removed to achieve decompression. Therefore, protocols vary according to the length of treatment, but typically the laser is activated for brief periods.

The nucleoplasty procedure is similar to the laser procedure but uses bipolar radiofrequency energy in a process referred to as Coblation technology. The technique consists of small, multiple electrodes that emit a fraction of the

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 - 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 - 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

energy required by traditional radiofrequency energy systems. The result is that a portion of nucleus tissue is ablated not with heat, but with a low-temperature plasma field of ionized particles. These particles have sufficient energy to break organic molecular bonds within tissue, creating small channels in the disc. The proposed advantage of this Coblation technology is that the procedure provides for a controlled and highly localized ablation, resulting in minimal therapy damage to surrounding tissue. Complications following percutaneous disc procedures include reherniation, disc instability, and device malfunction.

Microendoscopic discectomy is performed by passing an endoscope or dilating tube equipped with a camera to the operative site. The operative site is viewed on a monitor. In MED, the surgeon does not view the operative site directly. This technique has a steep learning curve. The advantages of this type of surgical technique are smaller incisions, less trauma to surrounding structures, and less recovery time than micro or open discectomy.

Minimally invasive lumbar decompression (MILD)

MILD (also known as image-guided minimally invasive lumbar decompression) is a percutaneous spinal decompression procedure used as a treatment of spinal stenosis. The MILD procedure is performed with the assistance of a contrast medium and fluoroscopic guidance. According to the manufacturer, the “*mild* Devices are designed to access the interlaminar space from the posterior lumbar spine, enabling the user to remove small portions of the lamina and preferentially resect and debulk the thickened ligamentum flavum, accomplishing a lumbar decompression.” This procedure does not involve a discectomy. The procedure can be performed on an outpatient basis under local anesthesia (Vertos Medical Mild Device Kit).

The original FDA premarket approval for the X-Sten MILD Tool Kit was granted in 2006 and is a set of specialized surgical instruments intended to be used to perform lumbar decompressive procedures for the treatment of various spinal conditions. In 2010, the FDA granted 510(k) premarket approval (K093062) for the modification of the X-

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Sten MILD Tool Kit (Vertos, San Jose, CA). According to the FDA approval letter, the Vertos Medical MILD Device Kit is substantially equivalent to the X-Sten MILD Tool Kit (K062038) and the Baxano Ultra Low Profile Rongeur and Access Tools (K062711) which had been granted FDA premarket approval at an earlier date. According to the Vertos MILD instructions for use, the device should be used for tissue resection at the perilaminar space, within the interlaminar space and at the ventral aspect of the lamina. The device is not intended to be used to remove the spinal disc.

Additional percutaneous discectomy devices have also been cleared by the FDA through the 510(k) substantial equivalence process, including the DeKompressor[®] Percutaneous Discectomy Probe (Stryker Instruments, Kalamazoo, MI), Herniatome Percutaneous Discectomy Device (Gallini Medical Devices, South Euclid, OH), and the Nucleotome[®] Probe Set (Clarus Medical, LLC, Minneapolis, MN). The FDA indications for these products is, "For aspiration of disc material during percutaneous discectomies in the lumbar, thoracic and cervical regions of the spine."

Other Percutaneous and/or Endoscopic Spine Surgery Procedures

Percutaneous posterior cervical nerve root decompression using an expandable intervertebral cervical cage has been explored as an alternative surgical treatment for single-level cervical radiculopathy. According to information on the FDA website, the "PMT Cervical Cage is an intervertebral fusion device intended to be used in cervical spinal fusion surgery. The FDA premarket approval stipulates that the PMT cervical cage is intended to be used as follows:

PMT Cervical Cage is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine (C3-C7) with accompanying radicular symptoms at one disc level. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

history and radiographic studies. Patients should have received at least six weeks of non-operative treatment prior to treatment with the device. Devices are intended to be used with autogenous bone graft and supplemental fixation, such as an anterior plating system (USFDA PMT Cervical Cage, 2013).

Definitions

Chemoneucleolysis: An injection of a drug to dissolve the disc, facilitating removal.

Curettage: The removal of unwanted tissue using a small, spoon shaped device called a curette.

Disc decompression: Reducing pressure within the disc by reducing the volume of nuclear material inside the disc.

Disc degeneration: The normal aging process of intervertebral discs that begins soon after puberty. The degenerative process begins with loss of water content of the nucleus (the center of the disc) and progresses to include decreased height of the disc, the development of annular fissures (cracks in the outer fibers), and circumferential enlargement of the disc.

Discectomy: Surgical removal of a part or all of an intervertebral disc, with or without removal of the nucleus pulposus. This surgery is performed via an open incision (considered the gold standard) allowing the surgeon the greatest ability to see and explore the surgical site.

Discogenic pain: Pain generated by the disc itself which is externally intact, as opposed to disc prolapse or herniation which put pressure on nearby nerve roots.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 - 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 - 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Herniated disc: Rupture of an intervertebral disc with protrusion of disc material and/or nucleus pulposus material into the intervertebral canal. This may result in nerve compression causing pain.

Lamina: A thin broad plate of bone forming the most posterior portion of the neural arch. The two laminae of each vertebra meet in the midline to form the spinous process.

Laminectomy: Surgical removal of a spinal lamina, often done to decompress underlying spinal nerves or to provide access for another surgical procedure.

Laminotomy: Partial removal of the spinal lamina to provide access to the neural canal.

Ligamentum flavum: Ligaments connecting adjacent spinal lamina.

Lumbar stenosis: A narrowing of the lumbar spinal canal.

The MacNab Clinical Outcome Measures:

- Excellent- No pain; no restriction of activity;
- Good- Occasional back or leg pain of sufficient severity to interfere with the ability to do normal work or capacity to enjoy leisure activities;
- Fair- Improved functional capacity but handicapped by intermittent pain of sufficient severity to curtail or modify work or leisure activities;
- Poor- No improvement or insufficient improvement to enable increase in activities; further operative intervention required.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Minimally invasive lumbar decompression (MILD): Decompression of the lumbar neural canal using indirect visualization (for example endoscopy or fluoroscopy).

Percutaneous: Access through the skin (puncture as opposed to "open" surgical incision).

Radicular pain: A type of pain that radiates to the upper or lower extremity directly along the course of a spinal nerve root. Radicular pain is caused by compression, inflammation, or injury to a spinal nerve root.

Spine anatomy: The spine is divided into three major sections: the cervical (neck), the thoracic (mid-back), and lumbar spine (lower back). These sections are made up of individual bones called vertebrae, which are the primary weight bearing structures of the torso alternating with intervertebral discs.

Surgical approaches:

- Percutaneous - The surgeon uses fluoroscopic imaging or other forms of indirect visualization during the surgical procedure. The surgery is performed using instruments passed directly through the skin (percutaneous).
- Endoscopic - The surgeon uses video or camera guidance during the procedure and performs the surgery through the endoscope working channel.
- Minimally Invasive - The surgeon directly visualizes the anatomy being operated on with the naked eye. The operative field may be developed using small profile (tubular or other) retraction to limit damage to surrounding normal tissues. The surgeon uses standard microdiscectomy techniques and instrumentation. Visualization may be assisted with a microscope or an endoscope.
- Open - The surgeon directly visualizes the anatomy being operated on with the naked eye. The surgery performed through an open incision utilizing direct visualization and muscle stripping and retraction. Standard

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

surgical instrumentation and techniques are used and may involve the removal of both bony and ligamentous structures.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services are Investigational and Not Medically Necessary:

When the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

CPT

22899	Unlisted procedure, spine [when specified as a percutaneous or endoscopic procedure for decompression for example DTRAX cage procedure]
62287	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar
62380	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar
0274T	Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy)

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

	and/or foraminotomy) any method under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; cervical or thoracic
0275T	Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar
64999	Unlisted procedure, nervous system [when specified as percutaneous decompression or laser procedures of cervical or thoracic spine]
HCPCS	
C2614	Probe, percutaneous lumbar discectomy
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar [DISC nucleoplasty]
ICD-10 Procedure	
0R533ZZ-0R5B4ZZ	Destruction of vertebral disc, percutaneous or percutaneous endoscopic approach [cervical, cervicothoracic, thoracic or thoracolumbar; includes codes 0R533ZZ, 0R534ZZ, 0R553ZZ, 0R554ZZ, 0R593ZZ, 0R594ZZ, 0R5B3ZZ, 0R5B4ZZ]
0RB33ZZ-0RBB4ZZ	Excision of vertebral disc, percutaneous or percutaneous endoscopic approach [cervical, cervicothoracic, thoracic or thoracolumbar; includes codes 0RB33ZZ, 0RB34ZZ, 0RB53ZZ, 0RB54ZZ, 0RB93ZZ, 0RB94ZZ, 0RBB3ZZ, 0RBB4ZZ]
0RN33ZZ-0RNB4ZZ	Release vertebral disc, percutaneous or percutaneous endoscopic approach [cervical, cervicothoracic, thoracic or thoracolumbar; includes codes 0RN33ZZ, 0RN34ZZ, 0RN53ZZ, 0RN54ZZ, 0RN93ZZ, 0RN94ZZ, 0RNB3ZZ, 0RNB4ZZ]

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

0S523ZZ-0S544ZZ	Destruction of vertebral disc, percutaneous or percutaneous endoscopic approach [lumbar or lumbosacral; includes codes 0S523ZZ, 0S524ZZ, 0S543ZZ, 0S544ZZ]
0SB23ZZ-0SB44ZZ	Excision of vertebral disc, percutaneous or percutaneous endoscopic approach [lumbar or lumbosacral; includes codes 0SB23ZZ, 0SB24ZZ, 0SB43ZZ, 0SB44ZZ]
0SN23ZZ-0SN44ZZ	Release vertebral disc, percutaneous or percutaneous endoscopic approach [lumbar or lumbosacral; includes codes 0SN23ZZ, 0SN24ZZ, 0SN43ZZ, 0SN44ZZ]

ICD-10 Diagnosis

All diagnoses

References

Peer Reviewed Publications:

1. Abrishamkar S, Salimi S, Pirmoradi H. Comparison the postoperation results of discectomy with nucleoplasty in single cervical disc herniation. *Adv Biomed Res.* 2018; 7:29.
2. Agarwal S, Bhagwat AS. Ho: Yag laser-assisted lumbar disc decompression: a minimally invasive procedure under local anesthesia. *Neurol India.* 2003; 51(1):35-38.
3. Ahn Y, Lee SH, Lee SC, et al. Factors predicting excellent outcome of percutaneous cervical discectomy: analysis of 111 consecutive cases. *Neuroradiology.* 2004; 46(5):378-384.
4. Aldahshory AR, Mashaly H, El Molla ST, et al. Comparative study of minimally invasive lumbar decompression versus decompressive laminectomy with posterolateral transpedicular fixation for the treatment of degenerative Lumbar canal stenosis. *Asian J Neurosurg.* 2020; 15(2):293-301.
5. Al-Zain F, Lemcke J, Killeen T, et al. Minimally invasive spinal surgery using nucleoplasty: a 1-year follow-up study. *Acta Neurochir (Wien).* 2008; 150(12):1257-1262.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

6. Amoretti N, David P, Grimaud A, et al. Clinical follow-up of 50 patients treated by percutaneous lumbar discectomy. *Clin Imaging*. 2006; 30(4):242-244.
7. Bai X, Lian Y, Wang J, et al. Percutaneous endoscopic lumbar discectomy compared with other surgeries for lumbar disc herniation: a meta-analysis. *Medicine (Baltimore)*. 2021; 100(9):e24747.
8. Benyamin RM, Staats PS, MiDAS Encore I. MILD® is an effective treatment for lumbar spinal stenosis with neurogenic claudication: MiDAS encore randomized controlled trial. *Pain Physician*. 2016; 19(4):229-242.
9. Brouwer PA, Brand R, van den Akker-van Marle ME, et al. Percutaneous laser disc decompression versus conventional microdiscectomy in sciatica: a randomized controlled trial. *Spine J*. 2015; 15(5):857-865.
10. Brouwer PA, Brand R, van den Akker-van Marle ME, et al. Percutaneous laser disc decompression versus conventional microdiscectomy for patients with sciatica: two-year results of a randomized controlled trial. *Interv Neuroradiol*. 2017; 23(3):313-324.
11. Brown LL. A double-blind, randomized, prospective study of epidural steroid injection vs. the mild® procedure in patients with symptomatic lumbar spinal stenosis. *Pain Pract*. 2012; 12(5):333-341.
12. Calisaneller T, Ozdemir O, Karadeli E, Altinors N. Six months post-operative clinical and 24 hour post-operative MRI examinations after nucleoplasty with radiofrequency energy. *Acta Neurochir (Wien)*. 2007; 149(5):495-500.
13. Casal-Moro R, Castro-Menéndez M, Hernández-Blanco M, et al. Long-term outcome after microendoscopic discectomy for lumbar disk herniation: a prospective clinical study with a 5-year follow-up. *Neurosurgery*. 2011; 68(6):1568-1575.
14. Ceylan A, Asik İ. Percutaneous navigable intradiscal decompression in treatment of lumbar disc herniation: A single-center experience. *Turk J Med Sci*. 2019; 49(2):519-524.
15. Chaterjee S, Foy PM, Findlay GF. Report of a controlled clinical trial comparing automated percutaneous lumbar discectomy and microdiscectomy in the treatment of contained lumbar disc disease. *Spine (Phila Pa 1976)*. 1995; 20(6):734-738.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

16. Chen HC, Huang TL, Chen YJ, et al. A minimally invasive endoscopic surgery for infectious spondylodiscitis of the thoracic and upper lumbar spine in immunocompromised patients. *Biomed Res Int*. 2015; 2015:780451.
17. Chen Z, Zhang L, Dong J, et al. Percutaneous transforaminal endoscopic discectomy compared with microendoscopic discectomy for lumbar disc herniation: 1-year results of an ongoing randomized controlled trial. *J Neurosurg Spine*. 2018; 28(3):300-310.
18. Chen Z1, Zhang L, Dong J, et al. Percutaneous transforaminal endoscopic discectomy versus microendoscopic discectomy for lumbar disc herniation: two-year results of a randomized controlled trial. *Spine (Phila Pa 1976)*. 2020; 45(8):493-503.
19. Chopko BW. Long-term results of percutaneous lumbar decompression for LSS: two-year outcomes. *Clin J Pain*. 2013; 29(11):939-943.
20. Chopko B, Caraway DL. MiDAS I (mild Decompression Alternative to Open Surgery): a preliminary report of a prospective, multi-center clinical study. *Pain Physician*. 2010; 13(4):369-378.
21. Cong L, Zhu Y, Tu G. A meta-analysis of endoscopic discectomy versus open discectomy for symptomatic lumbar disk herniation. *Eur Spine J*. 2016; 25(1):134-143.
22. Conger A, Schuster NM, Cheng DS, et al. The effectiveness of intraosseous basivertebral nerve radiofrequency neurotomy for the treatment of chronic low back pain in patients with Modic changes: a systematic review. *Pain Med*. 2021; 22(5):1039-1054.
23. Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-term outcomes following intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 5-year treatment arm results from a prospective randomized double-blind sham-controlled multi-center study. 2020; 29(8):1925-1934.
24. Garg B, Nagraja UB, Jayaswal A. Microendoscopic versus open discectomy for lumbar disc herniation: a prospective randomized study. *J Orthop Surg (Hong Kong)*. 2011; 19(1):30-34.
25. Gerszten PC, Welch WC, King JT Jr. Quality of life assessment in patients undergoing nucleoplasty-based percutaneous discectomy. *J Neurosurg Spine*. 2006; 4(1):36-42.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

26. Gibson JNA, Subramanian AS, Scott CEH. A randomized controlled trial of transforaminal endoscopic discectomy vs microdiscectomy. *Eur Spine J.* 2017; 26(3):847-856.
27. Haines SJ, Jordan N, Boen JR, et al. Discectomy strategies for lumbar disc herniation: results of the LAPDOG trial. *J Clin Neurosci.* 2002; 9(4):411-417.
28. Hellinger J, Stern S, Hellinger S. Nonendoscopic Nd-YAG 1064 nm PLDN in the treatment of thoracic discogenic pain syndromes. *J Clin Laser Med Surg.* 2003; 21(2):61-66.
29. Hermantin FU, Peters T, Quartararo L, Kambin P. A prospective, randomized study comparing the results of open discectomy with those of video-assisted arthroscopic microdiscectomy. *J Bone Joint Surg Am.* 1999; 81(7):958-965.
30. Hussein M, Abdeldayem A, Mattar MM. Surgical technique and effectiveness of microendoscopic discectomy for large uncontained lumbar disc herniations: a prospective, randomized, controlled study with 8 years of follow-up. *Eur Spine J.* 2014; 23(9):1992-1999.
31. Kreiner DS, MacVicar J, Duszynski B, Nampiarampil DE. The mild[®] procedure: a systematic review of the current literature. *Pain Med.* 2014; 15(2):196-205.
32. Lee DY, Shim CS, Ahn Y, et al. Comparison of percutaneous endoscopic lumbar discectomy and open lumbar microdiscectomy for recurrent disc herniation. *J Korean Neurosurg Soc.* 2009; 46(6):515-521.
33. Lewis RA, Williams NH, Sutton AJ, et al. Comparative clinical effectiveness of management strategies for sciatica: systematic review and network meta-analyses. *Spine J.* 2015; 15(6):1461-1477.
34. Li XC, Zhong CF, Deng GB, et al. Full-endoscopic procedures versus traditional discectomy surgery for discectomy: a systematic review and meta-analysis of current global clinical trials. *Pain Physician.* 2016; 19(3):103-118.
35. Lingreen R, Grider JS. Retrospective review of patient self-reported improvement and post-procedure findings for mild (minimally invasive lumbar decompression). *Pain Physician.* 2010; 13(6):555-560.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

36. Liu WG, Wu XT, Guo JH, et al. Long-term outcomes of patients with lumbar disc herniation treated with percutaneous discectomy: comparative study with microendoscopic discectomy. *Cardiovasc Intervent Radiol*. 2010; 33(4):780-786.
37. Liu X, Yuan S, Tian Y, et al. Comparison of percutaneous endoscopic transforaminal discectomy, microendoscopic discectomy, and microdiscectomy for symptomatic lumbar disc herniation: minimum 2-year follow-up results. *J Neurosurg Spine*. 2018; 28(3):317-325.
38. Manchikanti L, Singh V, Falco FJ, et al. An updated review of automated percutaneous mechanical lumbar discectomy for the contained herniated lumbar disc. *Pain Physician*. 2013; 16(2 Suppl):SE151-184.
39. McCormack BM, Bundoc RC, Ver MR, et al. Percutaneous posterior cervical fusion with the DTRAX Facet System for single-level radiculopathy: results in 60 patients. *J Neurosurg Spine*. 2013; 18(3):245-254.
40. Mekhail N, Costandi S, Nageeb G, et al. The durability of minimally invasive lumbar decompression procedure in patients with symptomatic lumbar spinal stenosis: long-term follow-up. *Pain Pract*. 2021; 21(8):826-835.
41. Merkow J, Varhabhatla N, Manchikanti L, et al. Minimally invasive lumbar decompression and interspinous process device for the management of symptomatic lumbar spinal stenosis: A literature review. *Curr Pain Headache Rep*. 2020; 24(4):13.
42. Nardi PV, Cabezas D, Cesaroni A. Percutaneous cervical nucleoplasty using coblation technology. Clinical results in fifty consecutive cases. *Acta Neurochir Suppl*. 2005; 92:73-78.
43. Nellensteijn J, Ostelo R, Bartels R, et al. Transforaminal endoscopic surgery for symptomatic lumbar disc herniations: a systematic review of the literature. *Eur Spine J*. 2010; 19(2):181-204.
44. Peng CW, Yeo W, Tan SB. Percutaneous endoscopic discectomy: clinical results and how it affects the quality of life. *J Spinal Disord Tech*. 2010; 23(6):425-430.
45. Phan K, Xu J, Schultz K, et al. Full-endoscopic versus micro-endoscopic and open discectomy: a systematic review and meta-analysis of outcomes and complications. *Clin Neurol Neurosurg*. 2017; 154:1-12.
46. Revel M, Payan C, Vallee C, et al. Automated percutaneous lumbar discectomy versus chemonucleolysis in the treatment of sciatica. A randomized multicenter trial. *Spine (Phila Pa 1976)*. 1993; 18(1):1-7.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

47. Ricciardi L, Stifano V, Sturiale CL, et al. Minimally invasive decompression with posterior elements preservation versus laminectomy and fusion for lumbar degenerative spondylolisthesis: A systematic review and meta-analysis of surgical, clinical and radiological outcomes. *Surg Technol Int*. 2020; 36:457-463.
48. Righesso O, Falavigna A, Avanzi O. Comparison of open discectomy with microendoscopic discectomy in lumbar disc herniations: results of a randomized controlled trial. *Neurosurgery*. 2007; 61(3):545-549.
49. Ruetten S, Komp M, Merk H, Godolias G. Full-endoscopic interlaminar and transforaminal lumbar discectomy versus conventional microsurgical technique: a prospective, randomized, controlled study. *Spine (Phila Pa 1976)*. 2008; 33(9):931-939.
50. Schizas C, Tsiridis E, Saksena J. Microendoscopic discectomy compared with standard microsurgical discectomy for treatment of uncontained or large contained disc herniations. *Neurosurgery*. 2005; 57(4 Suppl):357-360.
51. Shi R1, Wang F2, Hong X2, et al. Comparison of percutaneous endoscopic lumbar discectomy versus microendoscopic discectomy for the treatment of lumbar disc herniation: a meta-analysis. *Int Orthop*. 2019; 43(4):923-937.
52. Siemionow K, Janusz P, Phillips FM, et al. Clinical and radiographic results of indirect decompression and posterior cervical fusion for single-level cervical radiculopathy using an expandable implant with 2-year follow-up. *J Neurol Surg A Cent Eur Neurosurg*. 2016; 77(6):482-488.
53. Staats PS, Chafin TB, Golovac S, et al. Long-term safety and efficacy of minimally invasive lumbar decompression procedure for the treatment of lumbar spinal stenosis with neurogenic claudication: 2-year results of MiDAS ENCORE. *Reg Anesth Pain Med*. 2018; 43(7):789-794.
54. Tassi GP. Comparison of results of 500 microdiscectomies and 500 percutaneous laser disc decompression procedures for lumbar disc herniation. *Photomed Laser Surg*. 2006; 24(6):694-697.
55. Wang FF, Guo DD, Sun TT, Guan KK. A comparative study on short-term therapeutic effects of percutaneous transforaminal endoscopic discectomy and microendoscopic discectomy on lumbar disc herniation. *Pak J Med Sci*. 2019; 35(2):426-431.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

56. Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical versus nonoperative treatment for lumbar disc herniation: four-year results for the Spine Patient Outcomes Research Trial (SPORT). *Spine (Phila Pa 1976)*. 2008; 33(25):2789-2800.
57. Zhang B, Liu S, Liu J, et al. Transforaminal endoscopic discectomy versus conventional microdiscectomy for lumbar disc herniation: a systematic review and meta-analysis. *J Orthop Surg Res*. 2018; 13(1):169.
58. Zhou C, Zhang G, Panchal RR, et al. Unique complications of percutaneous endoscopic lumbar discectomy and percutaneous endoscopic interlaminar discectomy. *Pain Physician*. 2018; 21(2):E105-E112.

Government Agency, Medical Society, and Other Authoritative Publications:

1. American College of Occupational and Environmental Medicine. Practice Guidelines. Low Back Disorders. Effective March 7, 2019. Copyright © 2019. American College of Occupational and Environmental Medicine (ACOEM), All Rights Reserved.
2. Centers for Medicare and Medicaid Services. Decision Memo for Percutaneous Image-guided Lumbar Decompression for Lumbar Spinal Stenosis (CAG-00433N). January 9, 2014. Available at: <https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/PILD>. Accessed on April 10, 2024.
3. Centers for Medicare and Medicaid Services. National Coverage Determinations for Laser Procedures. NCD #140.5. Effective May 1, 1997. Available at <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=69&ncdver=1&DocID=140.5&bc=gAAAAAgAAAAAA%3D%3D>. Accessed on April 10, 2024.
4. Centers for Medicare and Medicaid Services. National Coverage Determination for Thermal Intradiscal Procedures (TIPs) NCD#150.11. Effective January 5, 2009. Available at: <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=324&ncdver=1&bc=AAAAQAAAAAA>. Accessed on April 10, 2024.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

5. Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine (Phila Pa 1976)*. 2009; 34(10):1066-1077.
6. Deer TR, Grider JS, Pope JE, et al. The MIST Guidelines: The Lumbar Spinal Stenosis Consensus Group Guidelines for Minimally Invasive Spine Treatment. *Pain Pract*. 2019; 19(3):250-274.
7. Gibson JN, Waddell G. Surgical interventions for lumbar disc prolapse. *Cochrane Database Syst Rev*. 2007;(2):CD001350.
8. North American Spine Society (NASS). Coverage Policy Recommendations. Guidelines. Available at: <https://www.spine.org/Research-Clinical-Care/Quality-Improvement/Clinical-Guidelines>. Accessed on April 10, 2024.
9. North American Spine Society (NASS). Clinical Guidelines. Evidence based clinical guidelines for multidisciplinary spine care. Diagnosis and Treatment of Low Back Pain. 2020. North American Spine Society. June 9, 2020. Available at: <https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf>. Accessed on April 10, 2024.
10. Rasouli MR, Rahimi-Movaghar V, Shokraneh F, et al. Minimally invasive discectomy versus microdiscectomy/open discectomy for symptomatic lumbar disc herniation. *Cochrane Database Syst Rev*. 2014;(9):CD010328.
11. U.S. Food and Drug Administration 510(k) Premarket Notification Summary. Providence Cervical Cage (Providence™ Medical Technology, Inc., Pleasanton, CA). K122801. May 24, 2013. Rockville, MD:FDA. Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K122801>. Accessed on April 10, 2024.
12. U.S. Food and Drug Administration 510(k) Premarket Notification Summary. X-Sten MILD Tool Kit (X-Sten Corp. San Jose, CA). K062038. Dec. 19, 2006. Rockville, MD:FDA. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf6/K062038.pdf. Accessed on April 10, 2024.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

13. U.S. Food and Drug Administration 510(k) Premarket Notification Database. Vertos Mild Device Kit (Vertos Medical, Inc. San Jose, CA). K093062. Modification Premarket Notification. February 4, 2010. Rockville, MD:FDA. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf9/K093062.pdf. Accessed on April 10, 2024.

Websites for Additional Information

1. U.S. National Library of Medicine. Discectomy. Updated March 21, 2022. Available at: <https://medlineplus.gov/ency/article/007250.htm>. Accessed on April 10, 2024.

Index

AccuraScope DND
 Automated Percutaneous Lumbar Discectomy (APLD)
 Baxano iO-Flex® System
 Cervical cage
 Cervical Deuk Laser Disc Repair
 Coblation
 Disc Decompression
 Discectomy
 Disc-FX™ System
 DTRAX
 Herniatome Percutaneous Discectomy Device
 Jho Procedure
 Laser Discectomy
 Microendoscopic Discectomy

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Minimally Invasive Lumbar Decompression (MILD)
Nucleoplasty
Nucleotome Probe Set
Percutaneous Endoscopic Discectomy
Providence Cervical Cage
Selective Endoscopic Discectomy™ (SED™)
Stryker DeKompressor Percutaneous Discectomy Probe
Yeung Endoscopic Spinal System (Y.E.S.S.)

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Document History

Status	Date	Action
Reviewed	05/09/2024	Medical Policy & Technology Assessment Committee (MPTAC) review. Updated Rationale and References section. Updated Coding section to add 22899 NOC code.
	09/27/2023	Updated Coding section; added HCPCS code C2614.
Reviewed	05/11/2023	MPTAC review. Updated References section.
Reviewed	05/12/2022	MPTAC review. References were updated.
Reviewed	05/13/2021	MPTAC review. References and Index sections were updated.
Reviewed	05/14/2020	MPTAC review. The Background, Index and References sections were updated.
Reviewed	06/06/2019	MPTAC review. Rationale, References, and Websites sections updated.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

Reviewed	07/26/2018	MPTAC review. The document header wording updated from “Current Effective Date” to “Publish Date.” Rationale, References, and Websites sections updated.
Reviewed	08/03/2017	MPTAC review. Updated the Description/Scope, Rationale, Background/Overview, References, Websites for Additional Information, Index and History sections.
	01/01/2017	Updated Coding section with 01/01/2017 CPT changes and clarified Description/Scope section.
Reviewed	08/04/2016	MPTAC review. Updated the Description/Scope, Rationale, Definitions, Reference, Index and History sections. Removed ICD-9 codes from Coding section.
Reviewed	08/06/2015	MPTAC review. Updated Rationale, References and History sections.
Reviewed	08/14/2014	MPTAC review. Updated Rationale, References and History sections.
Reviewed	08/08/2013	MPTAC review. Updated document to address minimally invasive lumbar decompression (MILD). Updated Description/Scope, Rationale, Background/Overview, Definitions, References, Index and History sections.
Reviewed	05/09/2013	MPTAC review. References updated.
Reviewed	05/10/2012	MPTAC review. Rationale, Background, Definitions and References updated.
	01/01/2012	Updated Coding section with 01/01/2012 CPT code descriptor changes.
Reviewed	05/19/2011	MPTAC review. Description, Rationale, Background, Definitions and References updated. Updated Coding section with 07/01/2011 CPT and HCPCS changes; removed C9729 deleted 06/30/2011.
Reviewed	02/17/2011	MPTAC review. Description clarified. Additional information added to Rationale and Definitions. References updated. Updated Coding section with 04/01/2011 HCPCS changes.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health’s Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient’s health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director

Percutaneous and Endoscopic Spinal Surgery

	04/29/2010	Information regarding the Vertos Minimally Invasive Lumbar Decompression (MILD®) device added to the Rationale. References updated.
Reviewed	02/25/2010	MPTAC review. Coding and references updated.
Revised	02/26/2009	MPTAC review. Position statement revised, title changed, rationale, background, coding and references updated.
Reviewed	11/20/2008	MPTAC review. Updated review date, references and history sections. Updated Coding section with 01/01/2009 CPT changes.
Reviewed	11/29/2007	MPTAC review. Updated review date, rationale, background/overview, references and history sections. The phrase “investigational/not medically necessary” was clarified to read “investigational and not medically necessary.”
Reviewed	12/07/2006	MPTAC review. Rationale and references sections updated.
Reviewed	03/23/2006	MPTAC review.
	11/18/2005	Added reference for Centers for Medicare and Medicaid Services (CMS) – National Coverage Determination (NCD).
Revised	07/14/2005	MPTAC review. Revision based on Pre-merger Anthem and Pre-merger WellPoint Harmonization.

Pre-Merger Organizations	Last Review Date	Document Number	Title
Anthem, Inc.	07/27/2004	SURG.00052	Chronic Spine Pain Treatments/Procedures (Minimally Invasive)
WellPoint Health Networks, Inc.	09/23/2004	3.07.04	Percutaneous Techniques for Disc Decompression

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

The requirements below are specific to the Florida Medicaid Managed Care Plan and are not a part of the Medical Policy or Clinical UM guideline approved by Elevance Health's Medical Policy and Technology Assessment Committee.

If the Florida Medicaid Managed Care Plan intends to deny coverage on the basis that a diagnostic test, therapeutic procedure, or medical device or technology is experimental or investigational, the Managed Care Plan shall submit a request for coverage determination to the Agency in accordance with rule 59G-1.035, F.A.C and Core SMMC Contract, Attachment II, Section VI.G.4.d.

Below is a list of the materials the plans are required to submit when they deny coverage as experimental/investigational:

- A. Include the CPT or HCPCS code(s)
- B. Include a list of other state Medicaid agencies and private insurers who cover the service
- C. Include information about the health service from the U.S. Food and Drug Administration
- D. Include known risks of the service and health outcomes of others who have received it
- E. Include a list of covered alternative services, if any, that could be used to treat the condition
- F. Identify a specific recipient needing the service
- G. Include the recipient's health history
- H. Include the disease information necessitating the requested service
- I. Include a rationale for the immediacy of the review

Additional required information

- A. Submit the rationale used to preliminarily indicate the service is experimental/investigational
 1. Include peer-reviewed journal articles in PDF format with links to the online articles
 2. Include evidence-based clinical guidelines reviewed by the plan
- B. Submit direct contact information (name, phone number, & email address) for the Medical Director